ASCO GUIDELINES Bundle

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2021 All rights reserved ASCOICPi10213b ASCO believes that cancer clinical trials are vital to inform medical decisions and improve cancer care and that all patients should have the opportunity to participate. Additional information, which may include data supplements, slide sets, and other clinical tools and resources, is available at www.asco.org/supportive-care-guidelines. Disclaimer is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y Guideline. is resource is a practice tool based on ASCO ® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. is pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. e practice guidelines and additional information are available at www.asco.org/ supportive-care-guidelines. Copyright © 2021 by American Society of Clinical Oncolog y. All rights reserved. Source Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor erapy: ASCO Guideline Update. J Clin Oncol. 2021. Abbreviations ACC, American College of Cardiolog y; AChR, acetylcholine receptor; ACTH, adrenocorticotropic hormone; ADL, activities of daily living ; AE, adverse event; AHA, American Heart Association; AKI, acute kidney injury; ANA, antinuclear antibody; ANC, antineutrophil cytoplasmic antibodies; ANCA, antineutrophil cytoplasmic antibodies; ATG, antithymocyte globulin; BAL, bronchoalveolar lavage; BNP, brain natriuretic peptide; BSA, body surface area; CCP, citrullinated protein antibody; CK, creatine kinase; CMV, cytomegalovirus; CPK, creatine phosphokinase; CRP, C-reactive protein; CT, computed tomography; CTCAE, Common Terminolog y Criteria for Adverse Events; CTLA-4, cytotoxic T-cell lymphocyte-4; CTPA, computed tomography pulmonary angiography; CXR, chest x-ray; DIC, disseminated intravascular coagulation; DIHS, drug-induced hypersensitivity syndrome; DKA, diabetic ketoacidosis; DLCO, diffusing capacity of lung for carbon monoxide; DM, diabetes mellitus; DMARD, disease-modifying antirheumatic drug ; DRESS, drug reaction with eosinophilia and systemic symptoms; DVT, deep vein thrombosis; EBV, Epstein-Barr virus; ED, emergency department; EGD, esophagogastroduodenoscopy; EMG, electromyography; EMS, emergency medical services; ESR, erythrocyte sedimentation rate; FSH, follicle-stimulating hormone; FT4, free thyroxine; G, grade; G-CSF, granulocyte-colony stimulating factor; GPI, glycosylphosphatidylinositol; Hgb, hemoglobin; HHV6, human herpesvirus 6; HIV, human immunodeficiency virus; HSV, herpes simplex virus; ICPi, immune checkpoint inhibitor; ICU, intensive care unit; IgG, immunoglobulin G; IL, interleukin; INR, international normalized ratio; irAE, immune-related adverse event; IV, intravenous; IVIG, intravenous immunoglobulin; LDH, lactate dehydrogenase; LH, luteinizing hormone; LLN, lower limit of normal; LMWH, low-molecular-weight heparin; MGFA, Myasthenia Gravis Foundation of America; MRI, magnetic resonance imaging ; N/A, not applicable; NCS, nerve conduction study; NIF, negative inspiratory force; NSAID, nonsteroidal anti-inflammatory drug ; PB, peripheral blood; PCP, primary care practioner; PCR, polymerase chain reaction; PD-1; programmed death 1; PD-L1, programmed death ligand 1; PE, pulmonary embolism; PEX, plasma exchange; PJP, Pneumocystis jirovecii pneumonia; PNH, paroxysmal nocturnal hemoglobinuria; PPI, proton pump inhibitor; PT, prothrombin time; PTT, partial thromboplastin time; PTU, propylthiouracil; RF, rheumatoid factor; RPR, rapid plasma reagin, SCAR, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; SSKI, potassium iodide; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TB, tuberculosis; TENS, toxic epidermal necrolysis; TNF, tumor necrosis factor; TPO, thyroid peroxidase; TRAb, thyroid-stimulating hormone receptor antibody; TSH, thyroid-stimulating hormone; TSI, thyroid-stimulating immunoglobulin; TTE, transthoracic echocardiogram; TTP, thrombotic thrombocytopenic purpura; ULN, upper limit of normal; UTI, urinary tract infection; VC, vital capacity; VKA, vitamin K agonist

• Cover